缬沙坦对高血压胰岛素抵抗的影响

The effects of valsartan on insulin resistance in essential hypertension

目的探讨缬沙坦对高血压患者胰岛素抵抗的影响。方法64例原发性高血压患者口服缬沙坦初始量80 mg,每天早晨口服,治疗10周后,采静脉血测定空腹胰岛素及空腹血糖,计算胰岛素敏感性指数。结果缬沙坦治疗10周后患者的收缩压(SBP)和舒张压(DBP)均降低,SBP由(151±14.9)mm Hg降至(124±10.2)mm Hg;DBP由(94.2±13.8)mm Hg降至(79.2±6.5)mm Hg(P<0.05);空腹胰岛素水平较治疗前降低,胰岛素敏感性指数较治疗前显著升高,分别为(15.74±3.14)mu/L降至(10.3±0.64)mu/L和(-4.26±0.50)升高至(-3.82±0.35)(P<0.05)。结论缬沙坦可有效降低和改善胰岛素抵抗。

Objective To discuss the effects of valsartan on insulin resistance in essential hypertension （ISR）, Methods 64 patients with essential hypertension were accepted valstartan 80rag, qd for 10 weeks at every morning. Serum concentration of fasting insulin and gluscose were measured. Insulin-sensitivity index（ISI） was calculated to evaluate the change of ISR after treatment. Results After treatments with valsartan for 10 weeks, the blood pressure decreased, both in SBP and DBP. SBP decreased from （151± 14.9）mmHg to （124 ± 10.2）mmHg; DBP decreased from （94.2 ±13.8） mmHg to （ 79.2 ±6.5 ） mmHg （ P 〈 0.05 ） ; Serum concentration of fasting insulin decreased and insulin-sensitivity index （ISI） significantly increased after treatments. Serum concentration of fasting insulin decreased from （15.74 ± 3.14）mu/L to （10.3±0,64）mu/L,ISI increased from （-4,26±0.50） to （ -3.82±0,35）（P〈0.05）.Conelusion Vksartan can decrease or improve insulin resistance in essential hypertension（ISR）.